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Abstract 
Recognizing the increasing concern about the potential health effects of 
genetically modified foods, this research provides a framework for economic 
value of monitoring genetically modified food for their potential long-term human 
health effects.  This is with the view of helping policy makers improve resource 
allocation decisions in the face of competing public health initiatives.  Using a 
hypothetical population exposed to a hypothetical product, we estimate the health 
value associated with a post-market surveillance initiative.  The analysis indicate 
that the principal challenge confronting decision makers in the implementation of 
post-market surveillance initiatives is prioritising products for monitoring given 
the uncertainty associated with outcomes and effects. 
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1. Introduction 
Although traditional foods have always presented risks of health effects (e.g., 
ischemic heart diseases, diabetes and cancer), they have been often been accepted as 
tolerable by-products to their nutritional benefits. The cost of these health risks has been 
determined to be significant in Canada (Choi and Pak, 2002) and in the United States 
(Mokdad et al., 2003).  However, the advent of genetically modified (GM) foods has 
unleashed a renewed interest in the potential effect of food consumption on long-term 
health, influencing research and policy discussions in many countries.  For example, the 
Royal Society of London (1998) called on the UK government to implement post-market 
surveillance of GM foods.  This led to the Advisory Committee on Novel Foods and 
Processes (ACNFP), which advises the UK Food Standards Agency, to recommend that 
the FSA undertake a feasibility study on conducting post-market monitoring of food 
consumption.   2
The Royal Society of Canada (2001) also recommended post-market surveillance 
of GM foods because of the uncertainty of their long-term health effects.  The report 
identified three potential sources of human health risks presented by GM foods: possible 
creation of novel toxicants, possible shifts in the nutrient content of the food, and the 
possible creation of novel allergens.  The authors of the report note (p. 71) that:  
In fact, there are no validated reports of allergic reactions to currently marketed GM 
foods as a result of the transgene protein. However, the potential risk for development of 
toxic or allergic reactions to GM foods will likely increase with advances in the scope 
and range of genetic modifications, wider acceptance of GM foods, increase in total 
dietary exposure to novel proteins, introduction of a greater variety of these foods, and 
more innovative transgenic combinations. 
As a result of their concern for the potential human late health effects of GM food 
products, the Royal Society of Canada, like its counterpart in the UK, recommended the 
development of post-market surveillance mechanisms for GM foods if there are data to 
indicate their effectiveness to detect the late health effects among consumers exposed to 
such products.   
Various joint expert panels constituted by the Food and Agriculture Organization 
and the World Health Organization and the European Union and the United States also 
made similar allusions to post-market surveillance as a means to minimize the potential 
effects of new GM foods in human health.  For example, EU-US governments’ 
Biotechnology Consultative Forum, which met four times between September and 
December 2000, considered the issues of traceability and monitoring, among others. It 
noted that mandatory monitoring was necessary whenever unanswered questions 
regarding specific health, environmental and/or safety concerns are raised about a new   3
product approved for marketing as well as when companies wish to make claims for 
benefits from the use of GM crops or foods.  Likewise, the January 2001 joint 
FAO/WHO consultative meeting argued that monitoring needs to be conducted for both 
potential beneficial and adverse effects.  The panel (p. 35) note that:  
The same problems apply to the detection of potential long-term beneficial health effects. 
Nevertheless, it was recognised that genetically modified foods intended to produce 
nutritional effects are under development for use in developed and developing countries. 
In such cases, a change in nutrient levels in a particular crop plant may impact overall 
dietary intake and it would be important to monitor changes in nutrient levels in such 
foods and evaluate their potential effect on nutritional and health status. 
Health officials in countries where governments are heeding the calls for post-
market surveillance policy initiatives are concerned about the implications of such 
initiatives on their already constrained budgets in the face of such current problems as 
foodborne diseases.  At the same time, because of potential international trade 
implications, there is concern about post-market surveillance of these products even in 
countries where there is no current policy discourse about these initiatives.   
The purpose of this paper is to present a framework for assessing the health value 
of post-market surveillance programs with the view of providing public health officials 
with a decision tool to facilitate effective resource allocation in the face of potential 
health risks from GM foods.  We draw on methods that have been used extensively in 
health economics in estimating the cost of injury (Cutler and Richardson, 1998) and 
quality of life effects of diseases (WHO, 2001).  Since these methods have been used to 
address known situations, we have adapted them to account for the uncertainty 
surrounding potential health risks emanating from exposure to GM foods and embedded   4
decision criteria within them.  The next section provides an overview of post-market 
surveillance and its application to human health and food.  We also present the challenges 
associated with the implementation of implementing post-market surveillance protocols 
specifically for a particular class of food products.  We note that in spite of these 
challenges, the decision to implement such policies will ultimately be imposed by 
administrative fiat (as seen in the case of the EU’s GM food traceability legislation 
(Commission of the European Communities, 2001)), and thus policy makers need to have 
tools that allow them do the best under the circumstances.   We present a test of the 
framework with a hypothetical population exposed to a hypothetical genetically modified 
food product. 
 
2.  Post-Market Surveillance of Late Health Effects from Food 
Post-market surveillance is the process of collecting, collating and analyzing 
health data associated with particular products after they have been introduced into the 
marketplace with the view to maximizing their safety and efficacy and minimizing their 
potential side effects.  Post-market surveillance has been used for a long time in the 
prescription drugs and medical device industries to maximize safety and efficacy as well 
as to help balance effectiveness against risks and affordability.  Because of its success in 
these industries, proponents of post-market surveillance believe it can address some of 
the uncertainty surrounding long-term health effects of GM food exposure, which would 
add another level of safety to existing protocols (Office of Technology Assessment at the 
German Parliament, 2000).     5
However, the difficulty of implementing post-market surveillance in the food 
industry is not lost in the debate.  Katzek and Gassen (2000), for example, observe that 
despite the risks associated with the consumption of novel foods, practical and systematic 
evaluation of potential negative long-term effects and methodological protocols and legal 
frameworks do not currently exist.  The Canadian Biotechnology Advisory Committee 
(2001) also observed that there are many difficulties in conducting GM food post-market 
surveillance, noting that these difficulties are only going to get more complex given the 
new products in the innovation pipeline.  The Royal Society of Canada (2001, p.73), 
echoed this difficulty by noting the paucity of existing relevant data collection and 
analysis protocols after recommending the development of mechanisms for after-market 
surveillance of GM foods incorporating novel proteins. Similarly, the first Joint 
FAO/WHO Expert Consultation on Food Derived from Biotechnology (2000, p. 32) 
noted that: 
. . . the issue of long-term effects from the consumption of genetically modified foods and 
noted that very little is known about the potential long-term effects of any foods. In many 
cases, this is further confounded by wide genetic variability in the population, such that 
some individuals may have a greater predisposition to food-related effects. In this 
context, the Consultation acknowledged that for genetically modified foods, the pre-
marketing safety assessment already gives assurance that the food is as safe as its 
conventional counterpart. Accordingly it was considered that the possibility of long term 
effects being specifically attributable to genetically modified foods would be highly 
unlikely. Furthermore, . . . observational epidemiological studies would be unlikely to 
identify any such effects against a background of undesirable effects of conventional 
foods.   6
The EU-US Biotechnology Consultation Forum (2000) also noted that 
implementing a post-market surveillance on a broad basis is near impossible.  Therefore, 
it advised that “a detailed plan for mandatory monitoring should be established on a case-
by-case basis,” (p. 12).  The Forum also recommended limited licenses as a means “to 
enforce effectively the obligation to monitor. For this purpose the limitation of the 
duration of marketing approvals may be an appropriate instrument. For these marketing 
approvals, continued approval would be based upon the results of the monitoring,” (p. 
13).  However, concerns about the potential hazards of GM foods are motivating certain 
countries, such as the UK, to assess the feasibility of a post-market surveillance system 
for food (Elliot, 1999).   
 
3.  Description of the Framework 
Population health protection resources have been allocated for many years using 
summary measures of population health, such as quality adjusted life years (QALYs) and 
disability-adjusted life years (DALYs) (Murray and Lopez, 2001).  They have also been 
used to estimate population health values (Moore et al., 1993) and compare changes in 
population health values in different periods (Cutler and Richardson, 1998).  These 
summary measures are structured to fall between 0 (death) and 1 (perfect health), with 
values in between indicating the intensity of living with an undesirable condition.   
If r is the discount rate, Qt is the quality life indicator, Pt is the socio-economic 
value in year t and k and T are the beginning and terminal years under consideration, then 
for each cohort group i, with population, wt, the present value of the health capital, Vi, is 
defined as:   7
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The socio-economic value is a sum of two values: social value, defined to encompass the 
value that is placed on human life with or without economic activity (Riley, 1993; Miller, 
1990), and economic value, defined as the average cohort income.  This may be obtained 
from the tax returns.  
The population health capital, V, is the sum of the health capital for all cohort 
groups, N.  We may present this algebraically as follows: 
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It has been argued that the effectiveness of pre-market assessment of GM foods 
minimizes potential adverse effects to a small segment of the population (FAO/WHO, 
2001; Donaldson and May, 1999).  However, beneficial effects of GM foods may be over 
a wider proportion of the population.  Therefore, we assume in this framework that only a 
fraction of each cohort population, αi, will develop a health condition, d, upon exposure 
to a particular GM food.  We can define the health capital of each cohort after exposure 
as the sum of the health capital of those with condition d and those without.   
Algebraically, this is: 
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where l is the unaffected population and j is the affected population in each cohort, i.e.:   
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where the probability that condition d will result from the exposure is cdt and Pjt and Qjt 
are the value and quality of life indicators associated with condition d.  All other   8
variables are as defined.  The expected population health capital resulting from GM food 
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The implementation of a post-market surveillance of potential human late health 
effects of GM foods is expected to alter the proportion of the population developing 
condition d, and its effects on health capital.  Thus, we can modify Equation (4) to reflect 
the effect of the intervention thus: 
(6) 
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where the superscript m indicates the effect of the intervention and the equivalent 
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The economic value of post-market surveillance, VS, is the difference between 
health capital with the intervention, VM, and without the intervention, VG. That is: 
(8)  SMG VVV =−  
A decision to implement a post-market surveillance system for particular 
conditions may be made on the relationship between VS and the cost of implementing the 
system, CS.   If VS/CS > 1, then the surveillance system creates more value than it costs, 
supporting its implementation, ceteris paribus.  If we are comparing two situations, 1 and 
2, and V1/C1 > V2/C2, then resources may be allocated to reflect the relative surveillance 
value-cost ratios.  If resources are constrained, such that C1+C2 > C available resources, 
then Situation 1 will be ranked over Situation 2 given the preceding condition.     9
  In the development of the foregoing framework, we have assumed that the 
variables are not only measurable but that they are also accessible.  The challenges of 
obtaining the changes in socio-economic values as a result of exposure to GM foods may 
be difficult to overcome because of causative effects of other variables such as education 
and training as well as experience on the job.  Therefore, it may become imperative for 
policy makers to ensure that cohort group samples assembled for the purpose of post-
market surveillance are structured to be randomized on the population.  This will help 
capture the differences in the value of variables determined by other effects other than the 
exposure to GM foods to be captured and separated.   
 
4. Framework  Implementation 
Although there is currently no evidence of GM foods causing any health condition 
in humans, suppose for the sake of argument, that exposing Canada’s population to a 
particular GM food results in a condition d.  Suppose also that the proportion of the 
population that is affected, α, and the socio-economic effects of the condition are, as 
expected, uncertain a priori.  Population health protection officials may simulate the 
health value of the GM food surveillance under alternative plausible values for all the 
uncertain or unknown variables – α, the probability of condition d occurring, cdt, discount 
rate, r, socio-economic impact on affected populations, Pdt and survival rates, sdt.   
For base reference value, we draw from a number of sources: WHO for QALY 
estimates, Canada Customs and Revenue Agency (CCRA) for economic value by cohort 
group, Health Canada for survival tables, and the health economics literature for other 
parameters necessary for the implementation of the framework.  For example, the WHO’s   10
Global Burden of Disease (2000) has detailed and extensive data on disability adjusted 
life years (DALYs) for 109 disease conditions and more than 500 sequelae for North 
America and the six other WHO regions reported by cohort groups.  The CCRA reports 
average income by cohorts and Health Canada has data on survival rate data by cohorts 
while Miller (1990) has estimated the social value of an anonymous person as $75,580 
(Canadian). The most common discount rate used by health economists is 3 percent (Choi 
and Pak, 2000), and it is used here to run the different scenarios.  It was assumed in all 
the simulations that the expected lifespan for each cohort is 85 years.   
 
5.  Results and Discussion 
  We assessed the value of post-market surveillance of a negative effect resulting 
from exposing the Canadian population as it existed in 2001 to a particular GM food 
under six exposure and post-market surveillance scenarios, plus the base (pre-exposure) 
scenario (Table 1).  The scenarios were based on plausible values for the proportion of 
the population that is affected and the economic and social impacts of the exposure as 
well as discount rates and the cohorts that are affected.  The post-market surveillance 
scenarios included these in addition to the time it took for information emanating from 
the surveillance to be collected, analyzed, causality established and amelioration policy 
implemented to address the observed condition, d, affecting the identified population 
segment.  We have structured the scenarios to illustrate the potential effects of the 
different variables on the health value of the exposure and the health value of post-market 
surveillance.  For example, in Scenario 2, we assume that 10 percent of all cohorts are 
affected by the condition.  The condition leads to a 15 percent reduction in economic   11
income (sickness resulting in lower productivity) and 20 percent reduction in social value 
(e.g., inability to support for friends, family and community).  For surveillance effect 
scenarios, SE3, e.g., assumes that the surveillance response time – i.e. time between 
starting a surveillance system and implementing an amelioration policy – is five years, 
and leads to 4 percent of affected population cohorts from Scenario S3 becoming free of 
the condition (i.e., 1 percent do not fully recover) and economic and social values 
increase to 95 percent of pre-condition values.  We assume that surveillance results in the 
restoration of Q-index to its base value. 










Response Time  Q Index 
Base  - 100% 100% -  QBASE 
S1  10% 90% 90% - Q
1 
S2  7% 85% 80% - Q
2 
S3  5% 80% 75% - Q
3 
S4  5% 80% 80% - Q
3 
Surveillance Effect 
SE1  3% 95% 95% 10 years  QBASE 
SE2  3% 95% 99% 10 years  QBASE 
SE3  1% 95% 95% 5 years  QBASE 
SE4  1% 95% 90% 5 years  QBASE 
 
The total and per capita health capital for the different cohorts are presented in 
Table 2.  It shows that the lifetime health capital for someone born in 2001 over a 
potential lifespan of 85 years is about $2.92 million.  This is similar to value of life 
estimated by the US FDA and the EPA (Riley, 1993).  For someone who is 80 years in 
2001, the remaining potential life health value is estimated as $543,841.  The total 
potential health value for people born in 2001 is $4,470 billion compared to $5,566 
billion for people 35 years in 2001.    12
Figure 1 shows the estimated lost health value per capita under the defined 
scenarios in Table 1.  Conducting the analysis under per capita conditions eliminates the 
mortality effects of the scenarios embedded in the Q-index.  The figure shows that the 
highest losses occurred for all cohort groups under S2 while the least losses occurred 
under S1.  Cohort 7 experienced the highest per capita losses under all scenarios.  The per 
capita health value loss for Cohort 7 ranged from $34,735 under S1 to $44,615 under S2.  
The order of the per capita health loss may be explained by the fact it has the highest 
remaining life total value (i.e., the product of total remaining life and average remaining 
life social and economic value).  On the other hand, Cohort 17 had the least losses under 
all scenarios because they had the lowest remaining life total value.  We would have 
expected that health value loss under S3 would be lower than S2 given the higher 
economic and social impacts as well as higher Q-index under the latter.  However, it 
seems that the fact that a lower proportion of the population was affected by the condition 
under S3 made the difference.   
A summary of the total population remaining lifetime health values under the 
alternative scenarios and interventions is presented in Table 3.  It shows that the total 
health value prior to exposure for the population is about $57,000 billion.  This is the 
present value of the current population of the country over the next 85 years, discounted 
at 3 percent.  The strictness of our present population assumption limits the analysis to 
particular population cohorts.  It has also assumed static current life tables and Q-indices, 
i.e., making room for no medical and other improvements that increase life expectancies 
and quality of life beyond what they are today.  The health value lost is the difference 
between the total health value under each scenario and the value under the base scenario.    13
Thus, Scenario S2 exhibited a higher loss ($816 billion) than all other scenarios, same as 
was found under the per capita analysis. The value of the post-market surveillance system 
was highest under SE3 and lowest under SE1.  What is interesting is that while we 
expected scenarios with higher health value losses to yield higher surveillance values, we 
found that the relationship is not that straight forward. The recovered value ratio is the 
proportion of health value loss under each scenario or condition that is recovered by the 
post-market surveillance system.  In our examples, we found that S3 presented the 
highest recovered value ratio of about 69 percent, while S1 presented the lowest, less than 
50 percent.  We also find that the recovered value ratios for the shorter surveillance 
response time scenarios were higher than those for the longer surveillance response time 
scenarios. 
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Table 2:   Total Population and Per Capita Remaining Lifetime Health Capital by Cohort 
 
Different conditions can be ranked by their corresponding post-market 
surveillance intervention values.  Thus, if we thought of the preceding four scenarios as 
four different conditions emanating from exposure to four different GM food products, 
we can rank them in ascending value order to decide which condition would produce the 
highest value.  The implementation of each of the surveillance programs may have 
different costs depending on the population and the required data.  Policy makers can 
subject their value rankings to the costs involved in implementing surveillance programs 
for each of the conditions.  The highest value to cost ratio offers policy makers the 




Group  Age in 2001  Remaining Health 
Value/Person ($M) 
Total Remaining Lifetime Health 
Value ($B) 
1  0-4                      2.92                4,601.56  
2  5-9                      2.96                5,227.00  
3  10-14                      3.02                5,343.62  
4  15-19                      3.08                5,338.16  
5  20-24                      3.09                5,281.93  
6  25-29                      3.08                5,107.28  
7  30-34                      3.03                5,172.94  
8  35-39                      2.94                5,565.87  
9  40-44                      2.80                4,997.30  
10  45-49                      2.63                3,859.30  
11  50-54                      2.42                2,816.48  
12  55-59                      2.18                1,673.50  
13  60-64                      1.91                   951.11  
14  65-69                      1.62                   542.80  
15  70-74                      1.30                   274.03  
16  75-79                      0.94                   103.15  
17  80+                      0.54                     38.72    15
Table 3:  Total Remaining Lifetime Health Values by Scenarios 
Scenario  Total Health Value 
($B) 






Base             56,894.75   -  -   
S1             56,207.16                  687.59  -  48%
S2             56,078.18                  816.57  -  60%
S3  56,148.40                 746.35  -  69%
S4  56,247.88                 646.87  -  67%
SE1             56,537.04                  357.71                 329.87   - 
SE2  56,565.74                 329.01                 487.56   - 
SE3  56,663.50                 231.25                 515.10   - 
SE4  56,678.37                 216.38                 430.49   - 
 
 
6. Conclusion   
This paper is a response to the increasing interest in post-market surveillance of 
potential human late health effects of GM foods.  Although there is currently no adverse 
incidence of human health that can be attributed to the GM foods, many governments are 
concerned about its potential.  This suggests that those calling for post-market 
surveillance may gain increasing audience in policy corridors.  There is, therefore, a need 
to anticipate the potential decisions that could arise when the time comes.  It is for this 
reason that we have developed this framework.  It is simple and flexible, but requires 
policy makers to have very a clear definition of the conditions they want to put under 
surveillance.  Without this clear definition, it is impossible to draw on the databanks, 
such as the WHO’s Global Burden of Disease, to facilitate effective decision-making.  
Also, without a clear definition of what it is that needs to be monitored, significant value 
of the post-market surveillance system will be lost collecting data and conducting 
analyses that do not address issues of relevance.     16
The value of post-market surveillance protocols in total may end up being 
significantly greater than the estimate for the health value alone as presented in this 
paper.  For example, when the framework is extended to incorporate other government 
policies surrounding food safety and trade as well as chain of custody for food products, 
and not just GM food, we can expect the value of post-market surveillance to increase.  
Hence, this research provides a stepping stone for thinking about how to model the 
complex issues embedded in post-market surveillance of food as well as ensuring that 
policy makers have the right perspective on the issues when it comes time for them to 
make resource allocation decisions vis-à-vis population health.     17
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